| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/22/2007 | CN101019824A Oral medicine composition containing salvianolic acid and its prepn |
| 08/22/2007 | CN101019823A Separately packed structural fatty milk, aminoacid and glucose injection composition and the prepn process |
| 08/22/2007 | CN101019822A Separately packed fatty milk, amino acid and glucose injection composition and the prepn process |
| 08/22/2007 | CN101019814A Application of non-depolarizing muscular relaxant in preventing and eliminating facial wrinkles |
| 08/22/2007 | CA2578325A1 Megestrol acetate suspension |
| 08/21/2007 | US7259273 preserving an organ; thiophosphate, (thio)sulfate analogs of lysophosphatidic acids |
| 08/21/2007 | US7259270 Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions |
| 08/21/2007 | US7259266 Benzopyran compounds useful for treating inflammatory conditions |
| 08/21/2007 | US7259262 Arylazole derivatives, their manufacture and use as pharmaceutical agents |
| 08/21/2007 | US7259261 Racemization and enantiomer separation of clopidogrel |
| 08/21/2007 | US7259250 C-nitroso compounds and use thereof |
| 08/21/2007 | US7259188 Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators |
| 08/21/2007 | US7259187 Tropolone derivatives |
| 08/21/2007 | US7259186 Salts of fenofibric acid and pharmaceutical formulations thereof |
| 08/21/2007 | US7259185 Containing glycerin to act as a stabilizer and a preservative and water or a pH buffer to provide a pH above 5; the amount of warfarin sodium that is degraded after at least 1 month at room temperature is 5% or less. |
| 08/21/2007 | US7259184 Treatment of arrhythmia and the production of analgesia and local anesthesia by administering 1-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(3-hydroxy-1-pyrrolidinyl)cyclohexane or a salt |
| 08/21/2007 | US7259183 Indole, indazole and indoline derivatives as CETP inhibitors |
| 08/21/2007 | US7259182 Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders |
| 08/21/2007 | US7259181 β crystalline form of perindopril tert-butylamine salt |
| 08/21/2007 | US7259180 Methods and compositions for treatment of macular and retinal disease |
| 08/21/2007 | US7259179 Kinase inhibitors |
| 08/21/2007 | US7259178 Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes |
| 08/21/2007 | US7259177 Containing an oxazole ring 2-phenyl-, furanyl- or thiophenyl-substituted; e.g., 2,2-Dimethyl-4-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-butyric acid; treating disorders of fatty acid metabolism, glucose utilization disorders, and also of disorders in which insulin resistance is involvolved |
| 08/21/2007 | US7259176 Process for the preparation of the insulin sensitizer |
| 08/21/2007 | US7259175 Alkanoic acids substituted with a group containing pyridinyl-, pyrimidinyl- or pyrazinyl-phenyl linked through a thiazolyl- or oxazolyl- phenyl group; e.g., 3-[4-(2-{2-[6-(2-Fluoro-phenyl)-pyridin-3-yl]-5-methyl-thiazol-4-yl}-ethoxy)-2-methyl-phenyl]-propionic acid; treating diabetes and atherosclerosis |
| 08/21/2007 | US7259174 1-(Hetero)aryl- and 3-substituted with a group containing an arylaldehyde oxime, e.g., 4-[5-(2-oxo-3-pyridin-4-yl-imidazolidin-1-yl)-pentyloxy]-benzaldehyde O-methyl-oxime; treating enteroviral infections |
| 08/21/2007 | US7259173 Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions |
| 08/21/2007 | US7259172 Inhibitors of β-lactamase |
| 08/21/2007 | US7259171 Di and trifluoro-triazolo-pyridines anti-inflammatory compounds |
| 08/21/2007 | US7259170 Macrolides containing pharmaceutical compositions |
| 08/21/2007 | US7259168 2-Aminoalkyl-thieno[2,3-d]pyrimidines |
| 08/21/2007 | US7259167 Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof |
| 08/21/2007 | US7259166 Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators |
| 08/21/2007 | US7259165 especially 3-sulfonylpyrazolo[4.3b]pyridines and 3-sulfonylpyrrolo[3.2b] and [2.3b]pyridines; treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor, such as attention deficit disorder; obsessive compulsive disorder; and withdrawal from drug, alcohol or nicotine |
| 08/21/2007 | US7259164 Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
| 08/21/2007 | US7259163 Viricides against herpes virus |
| 08/21/2007 | US7259162 Benzazole derivatives and their use as JNK modulators |
| 08/21/2007 | US7259161 For therapy of immune response, an autoimmune disease, a neurodegenerative, or a solid or hematologic malignancy |
| 08/21/2007 | US7259160 Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| 08/21/2007 | US7259159 Vitronectin receptor antagonists for treating and preventing osteoporosis, bone disorders |
| 08/21/2007 | US7259157 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists |
| 08/21/2007 | US7259156 17-(Quaternary amino-, phosphono- phosphino-, sulfo-, or carboxy-alkylamino)-substituted; extracellular heat shock protein-90 inhibitors, used as anticancer agents |
| 08/21/2007 | US7259155 Phosphonic diester derivatives |
| 08/21/2007 | US7259154 Pyrrolopyrimidines |
| 08/21/2007 | US7259153 Drug formulation and delivery using crystalline methylated cyclodextrins |
| 08/21/2007 | US7259152 Oral administration of Sulodexide in unit dosages suitable for the treatment of diabetic nephropathies in both macro and micro albuminic patients, producing immediate and lasting improvement in albumin excretion rate |
| 08/21/2007 | US7259151 AAV virions with decreased immunoreactivity and uses therefor |
| 08/21/2007 | US7259148 Hepatoprotective activity of 2′-p-hydroxybenzoylmussaenosidic acid |
| 08/21/2007 | US7259143 Administering an appropriate dosage schedule of a bone calcium resorption inhibitor and a toxic dose of a vitamin d without developing hypercalcemia |
| 08/21/2007 | US7259141 prepared via chemoenzymatic techniques; contain a 1,2,3-triazole moeity attached to the sugar group; glycosylating a vancomycin aglycone with a sugar transferase, then reacting with an alkyne via a 1,3-dipolar cycloaddition; treating vancomycin resistant infections |
| 08/21/2007 | US7259138 Anti-tumor agents |
| 08/21/2007 | US7258973 Oligonucleotide sequences for use in the diagnosis and treatment of colon cancer |
| 08/21/2007 | US7258879 Food product and process for manufacturing same |
| 08/21/2007 | US7258876 applying a mixture of melaleuca alternifolia extract oil, an immunostimulant and an antioxidant; treats most every type of infection caused by pathogenic organisms with little or no side effects. |
| 08/21/2007 | US7258875 Compositions and methods for topical treatment of skin infection |
| 08/21/2007 | US7258872 Chromone enteric release formulation |
| 08/21/2007 | US7258871 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 08/21/2007 | US7258866 M. canis-containing ringworm vaccine |
| 08/21/2007 | US7258859 Method for the treatment of multiple sclerosis |
| 08/21/2007 | US7258857 Rage-related methods for treating inflammation |
| 08/21/2007 | US7258851 Cholesterol reducing chewing gum composition and method of making the same |
| 08/21/2007 | US7258850 Methods and compositions for treating erectile dysfunction |
| 08/21/2007 | CA2493885C Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals |
| 08/21/2007 | CA2443285C Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| 08/21/2007 | CA2388610C Oral transmucosal drug dosage using solid solution |
| 08/21/2007 | CA2387600C Novel fusidic acid derivatives |
| 08/21/2007 | CA2379445C Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production |
| 08/21/2007 | CA2345494C Methods and apparatus for improved administration of fentanyl and sufentanil |
| 08/21/2007 | CA2332790C Controlled release lipoic acid |
| 08/21/2007 | CA2328730C Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
| 08/21/2007 | CA2320368C Composition comprising theanine |
| 08/21/2007 | CA2315827C Substituted pyridine and pyridazine compounds and their pharmaceutical use |
| 08/21/2007 | CA2304965C ((cyclo)alkyl substituted)-gamma-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders |
| 08/21/2007 | CA2294036C Polyallylamine polymers for treating hypercholesterolemia |
| 08/21/2007 | CA2288958C Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation |
| 08/21/2007 | CA2264066C Antiparasitic compounds isolated from fermentation of nodulisporium sp |
| 08/21/2007 | CA2257579C Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
| 08/21/2007 | CA2247966C Murine .alpha.(1,3)fucosyltransferase fuc-tvii, dna encoding the same and uses thereof |
| 08/21/2007 | CA2218664C New n-acylated 4-hydroxyphenylamine derivatives with analgesic properties and pharmaceutical compositions containing them |
| 08/21/2007 | CA2165995C Medicaments for the treatment of restenosis and arterial sclerosis |
| 08/21/2007 | CA2150940C Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 08/21/2007 | CA2099589C Enantiomerically pure .beta.-d-(-)-dioxolane-nucleosides |
| 08/17/2007 | CA2579188A1 Treatment of amyloid-related diseases |
| 08/17/2007 | CA2569776A1 Low flush niacin formulation |
| 08/16/2007 | WO2007092964A1 Bladder cancer treatment by using e09 and propylene glycol |
| 08/16/2007 | WO2007092963A1 Bladder cancer treatment involving determination of tumor enzyme level |
| 08/16/2007 | WO2007092888A2 Hcv ns5b inhibitors |
| 08/16/2007 | WO2007092802A1 Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| 08/16/2007 | WO2007092784A1 Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates |
| 08/16/2007 | WO2007092755A2 Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| 08/16/2007 | WO2007092751A2 Compounds and methods for modulating fx-receptors |
| 08/16/2007 | WO2007092727A1 Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators |
| 08/16/2007 | WO2007092645A2 Novel hcv inhibitor combinations and methods |
| 08/16/2007 | WO2007092638A1 Bicyclic sphingosine 1-phosphate analogs |
| 08/16/2007 | WO2007092558A2 Sulfonamide derivatives to treat infection with hepatitis c virus |
| 08/16/2007 | WO2007092531A2 Compounds and compositions as protein kinase inhibitors |
| 08/16/2007 | WO2007092469A2 Combination of organic compounds |
| 08/16/2007 | WO2007092458A1 Antidotes to exogenous neurotoxic agents |
| 08/16/2007 | WO2007092436A2 Compounds for treating inflammatory disorders, demyelinating disorders and cancers |
| 08/16/2007 | WO2007092435A2 11-beta hsd1 inhibitors |